Physician profile
Alan Silverman
NPI 1316039811
$5,098.67
in general payments reported to CMS, 2019-2025
29 companies · $764 in 2025
The $764 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $87.04 · 2021: $73.66 · 2022: $1,251 · 2023: $1,134 · 2024: $1,249 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.10 |
| Education | $116.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,960.12 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $522.95 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $416.87 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $325.99 | 2022-2025 | Sotyktu |
| Pfizer INC. | $216.73 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $191.50 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $186.54 | 2019-2024 | |
| Amgen INC. | $172.48 | 2022-2024 | Otezla |
| Hill Dermaceuticals, INC. | $150.00 | 2024 | Tolak |
| Regeneron Healthcare Solutions, INC. | $143.51 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $123.98 | 2019-2024 | |
| Genzyme Corporation | $97.69 | 2019-2023 | |
| Dermavant Sciences, INC. | $77.43 | 2023-2024 | Vtama |
| Incyte Corporation | $75.23 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.67 | 2022-2024 | Spevigo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $47.73 | 2022-2023 | Xtrac |
| Leo Pharma INC. | $46.66 | 2023 | Adbry |
| Ucb, INC. | $42.66 | 2021 | |
| Fresenius Kabi USA, LLC | $29.59 | 2023 | Idacio |
| Helsinn Therapeutics (U.S.), INC. | $27.45 | 2019-2022 | |
| Revance Therapeutics, INC. | $27.23 | 2024 | Daxxify |
| Medimetriks Pharmaceuticals, INC. | $22.59 | 2022 | |
| Journey Medical Corporation | $22.29 | 2019-2022 | |
| Sientra, INC. | $19.71 | 2020 | |
| Nabriva Therapeutics, Plc | $19.51 | 2022 | |
| Acera Surgical, INC. | $18.38 | 2022 | |
| Biofrontera INC. | $17.04 | 2022 | |
| Vyne Pharmaceuticals INC. | $13.05 | 2020 | |
| Genentech USA, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.